EU/3/16/1619

About

On 17 February 2016, orphan designation (EU/3/16/1619) was granted by the European Commission to Eyevensys SA, France, for DNA plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human TNFα p55 receptor linked to the human IgG1 Fc domain for the treatment of non-infectious uveitis.

In May 2017, Eyevensys SA changed name to Eyevensys SAS.

The sponsor’s address was updated in September 2020.

Key facts

Active substance
DNA plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human TNFα p55 receptor linked to the human IgG1 Fc domain
Disease / condition
Treatment of non-infectious uveitis
Date of first decision
17/02/2016
Outcome
Positive
EU designation number
EU/3/16/1619

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Eyevensys S.A.S
11 Rue Watt
Biopark Bâtiment B
75013 Paris
France
Tel. +33(0)184 791060
E-mail: contact@eyevensys.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating